Archive for the Category ◊ Ophthalmology ◊

• Friday, July 25th, 2014

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $13 per share, before underwriting discounts and commissions. All of […]

• Friday, January 24th, 2014

Google’s clandestine ‘[X]’ laboratory offers new details on its glucose-sensing contact lens project, saying that it’s looking for “expert partners” to help get the technology to market. Google (NSDQ:GOOG) is hoping to forge some new partnerships to support its newly unveiled smart contact lens, which is laden with sensors and transmitters that aim to help diabetics monitor […]

• Tuesday, January 21st, 2014

Google is developing smart contact lenses that measure the glucose levels in diabetics’ tears. If successful, Google’s newest venture could help to eliminate one of the most painful and intrusive daily routines of diabetics. People with diabetes have difficulty controlling the level of sugar in their blood stream, so they need to monitor their glucose […]

• Friday, January 17th, 2014

Google Inc. sent employees with ties to its secretive X research group to meet with federal regulators who oversee medical devices, raising the possibility of a new product that may involve biosensors from the unit that developed computerized glasses. The meeting included at least four Google workers, some of whom have connections with Google X – and […]

• Wednesday, December 11th, 2013

Israeli medtech company Lumenis files for an initial public offering worth $115 million. Lumenis Ltd., an Israeli medtech company that makes lasers used in eye surgery, urology and cosmetic medical procedures, filed today for an initial public offering worth $115 million. Yokneam, Israel-based Lumenis said it plans to trade on the NASDAQ stock exchange under […]

• Thursday, November 28th, 2013

Valeant Pharmaceuticals International Inc. will make its silicone hydrogel contact lenses in Rochester rather than in Ireland as originally planned, investing $106 million at Bausch & Lomb Inc.’s manufacturing facility here and adding 100 jobs, officials announced Monday. The work will bring $100 million in new investment into the Rochester economy and retain 1,050 jobs […]

• Tuesday, November 26th, 2013

Pixium Vision raises €15 million led by Sofinnova Partners PARIS, November 25, 2013 /PRNewswire/ — Funds to advance development of retinal implant systems that aim to restore vision in blind people Financing includes Bpifrance, through the InnoBio fund Pixium Vision (“Pixium”), a developer of innovative retinal implant systems that aim to restore vision in the […]

• Saturday, November 16th, 2013

Lumenis Receives US FDA and Japanese MHLW Clearance for Array(TM) LaserLink(TM) Pattern Scanning Device for Multi-Spot Retinal Laser Treatment SAN JOSE, CA–(Marketwired – Nov 15, 2013) – Lumenis Ltd., the world’s largest medical laser company for ophthalmic, surgical and aesthetic applications, today announced that the company has received US FDA and Japanese MHLW clearance for […]

• Friday, November 01st, 2013

GrayBug, LLC Appoints Michael O’Rourke as President & CEO BALTIMORE, Oct. 28, 2013 (GLOBE NEWSWIRE) — GrayBug, LLC, a company that focuses on the development of innovative injectable drug delivery systems to more effectively treat eye diseases, has announced the appointment of Michael O’Rourke as President & CEO, as well as Board Member. “I am […]

• Monday, October 07th, 2013

Synergetics USA Inc. reported net income of $1.4 million in the fourth quarter ended July 31, down 26 percent from the same period last year due to weak activity in emerging markets. “Our international results were softer than anticipated, driven by ongoing weakness in our base business and lower contributions from emerging markets compared to last […]